NICE gives Ferring's Firmagon lukewarm recommendation
This article was originally published in Scrip
Executive Summary
The HTA for England and Wales, NICE, has published final draft guidance recommending Ferring's Firmagon (degarelix) for hormone-dependent prostate cancer, but only in patients with spinal metastases who present with signs of the emergency condition spinal cord compression. This is a significant restriction, as the drug is approved in Europe to treat all hormone-dependent prostate cancer patients.